Cerebrolysin

Cerebrolysin is a preparation of low-molecular-weight peptides and amino acids derived from porcine brain proteins. It is approved in some countries for neurological conditions such as stroke and dementia, but it is not approved in the US.

Last reviewed 2026-10-25 by the PeptideWiki editorial team. Editorial policy.

Overview

Cerebrolysin is not a single peptide but a mixture produced by controlled enzymatic breakdown of proteins from pig brain. The resulting preparation contains short peptides and free amino acids, and its developers describe it as having activity resembling that of neurotrophic factors. It has been marketed for decades in parts of Europe, Asia and elsewhere, and it is among the most widely studied brain-derived peptide preparations.

Clinical research on cerebrolysin has focused on acute ischemic stroke, traumatic brain injury and dementia, including Alzheimer's disease and vascular dementia. Many trials have been conducted, with mixed results; some reported benefits on secondary or functional outcomes, while several large trials did not meet their primary endpoints. Systematic reviews have reached cautious conclusions. Because it is a biologically derived mixture, its composition is defined by the manufacturing process rather than a single sequence.

Structure

Cerebrolysin is a complex mixture obtained by standardized enzymatic hydrolysis of purified porcine brain proteins, followed by processing to remove high-molecular-weight material. The final product is described as containing a peptide fraction of low molecular weight, generally under about 10 kDa, together with free amino acids. It has no single defined sequence, and individual active components have not been fully identified. The product is supplied as an aqueous solution for injection or infusion, so lyophilized research forms are not typical.

Mechanism

Cerebrolysin is proposed to act through effects resembling neurotrophic factors such as brain-derived neurotrophic factor and nerve growth factor, including support of neuronal survival, synaptic plasticity and neurogenesis. Preclinical studies in cell culture and animal models have reported reduced neuronal death after injury, modulation of amyloid-related processes and effects on inflammatory pathways.

Because the preparation is a mixture, it is unclear which components are responsible for reported effects, and no single receptor has been identified. Whether the peptides cross the blood-brain barrier in meaningful amounts and how activity is maintained are open questions. The mechanistic evidence comes largely from preclinical studies, often conducted or supported by the manufacturer.

Research

Acute ischemic stroke

Several randomized trials have evaluated cerebrolysin started soon after acute ischemic stroke. A large trial in Asia, CASTA, did not meet its primary efficacy endpoint, though subgroup analyses were reported. Other trials, such as CARS, studied it during rehabilitation and reported improvements in motor function measures. Systematic reviews, including Cochrane reviews, have generally concluded that the evidence does not establish a benefit on death or dependency, while noting heterogeneity across trials.

Traumatic brain injury

Cerebrolysin has been studied in traumatic brain injury, including a randomized trial known as CAPTAIN that used a multidimensional outcome approach. Investigators reported signals in some outcome measures, but results have been debated because of methodology and trial size. Observational studies have also been published. Overall, the evidence in traumatic brain injury is considered preliminary. No regulatory authority in the US has evaluated it for this use.

Dementia

Trials in Alzheimer's disease and vascular dementia have assessed cognitive and global function scales over periods of weeks to months. Some reported improvements compared with placebo, particularly in short-term measures, but trials were often small and of variable quality. Meta-analyses have suggested possible effects while emphasizing the need for larger, independent, well-designed trials. Effects on longer-term disease progression have not been demonstrated.

Evidence quality

Cerebrolysin has an unusually large clinical literature for a peptide preparation, but its quality is uneven, with many small or industry-sponsored studies and inconsistent results in larger trials. Independent replication and standardized outcome reporting are limited. Its approval in some countries is based on national regulatory decisions, and its effectiveness remains a subject of debate. Readers should weigh the design and funding of individual trials carefully.

Regulatory status

Cerebrolysin is approved in some countries for neurological indications, which vary by jurisdiction. It is not approved by the FDA for any use in the US. It is not a recognized substance for US pharmacy compounding. For sport, check the current WADA Prohibited List.

Status changes often. See the regulatory tracker for dated updates.

Quality and identity testing

Because cerebrolysin is a mixture, standard single-peptide analysis does not apply, and the mass shown for sequence-defined compounds on this site is not relevant. Quality is established by the manufacturer's process controls, including source material, enzymatic hydrolysis conditions and molecular weight distribution, along with sterility, endotoxin and safety testing appropriate for a biological product. Analytical approaches include chromatographic fingerprinting, molecular weight profiling and amino acid analysis. Material of uncertain origin cannot easily be verified against the approved product. Viral and transmissible spongiform encephalopathy safety controls are particularly relevant for animal brain-derived products.

For a walkthrough of each section of a certificate, see how to read a COA.

Storage and stability

Cerebrolysin is supplied as a ready-to-use aqueous solution, and the approved product should be stored as stated on its labeling, typically at controlled room temperature or below, protected from light, and not frozen. Opened ampoules or vials should be used promptly to avoid contamination. For laboratory work, aliquoting under sterile conditions and adherence to manufacturer guidance are advisable, because stability data for altered storage conditions are not generally published.

Download the Cerebrolysin data sheet (PDF): sequence, masses, expected MS ions and handling on one printable page.

Latest research

Frequently asked questions

Related compounds

• Semax

  Semax is a synthetic heptapeptide developed in Russia as an analogue of the adrenocorticotropic hormone fragment ACTH(4-7), extended with a Pro-Gly-Pro tail. It is studied for neurotrophic signaling and in models of brain injury.

• Selank

  Selank is a synthetic heptapeptide developed in Russia, built from the immunomodulatory tetrapeptide tuftsin extended with a Pro-Gly-Pro tail. It is studied mainly for effects on anxiety-related behavior and immune signaling.

• Dihexa

  Dihexa is a small, chemically modified peptide-like analogue of angiotensin IV developed as a metabolically stabilized research compound. It has been studied in rodent models of cognitive impairment and is not approved for any use.

• Noopept

  Noopept is a dipeptide-derived small molecule, N-phenylacetyl-L-prolylglycine ethyl ester, developed in Russia as a nootropic research compound. It has been studied mostly in rodent models, with limited clinical data, and is not approved by the FDA.

References

1. PubMed: all indexed literature on Cerebrolysin
2. ClinicalTrials.gov: registered studies mentioning Cerebrolysin